西部超導(688122.SH):公司參與了C919大飛機相關材料的研製 取得相關產品的供貨資格
格隆匯12月11日丨西部超導(688122.SH)在2023年第三季度業績説明會上表示,2023年以來,公司與MRI、MCZ相關的超導線材和磁體業務較去年同期均有顯著增長,目前相關產品訂單飽滿。公司將持續開發MRI、MCZ相關技術在醫療、熱核聚變、半導體、光伏、及電力領域的應用,並與相關企業和單位加強業務拓展,形成更多的實質性合作。
公司參與了C919大飛機相關材料的研製,取得相關產品的供貨資格。未來公司將進一步拓展與相關企業和單位在大飛機相關業務上的合作。感謝您對公司的關注。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.